


## CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in *BRCA* Wild-Type and Mutated Models of Triple-Negative Breast Cancer

### Graphical Abstract



### Authors

Shawn F. Johnson, Cristina Cruz, Ann Katrin Greifenberg, ..., Violeta Serra, Elgene Lim, Geoffrey I. Shapiro

### Correspondence

e.lim@garvan.org.au (E.L.),  
geoffrey\_shapiro@dfci.harvard.edu (G.I.S.)

### In Brief

Johnson et al. show that CDK12 inhibition, mediated by the small molecule dinaciclib, disrupts residual or restored homologous recombination (HR) in *BRCA*-associated breast cancer, sensitizing to PARP inhibition. CDK12 inhibition also augments the degree of PARP inhibitor response in HR-deficient breast cancer. Combined CDK12-PARP inhibition is well tolerated in preclinical models.

### Highlights

- Dinaciclib is a potent inhibitor of CDK12 and disrupts homologous recombination
- Residual HR is a cause of de novo PARP inhibitor resistance in *BRCA*-mutated cancer
- Dinaciclib sensitizes resistant *BRCA*-mutated breast cancer models to PARP inhibition
- In HR-deficient cancer, dinaciclib augments the response afforded by PARP inhibition

### Accession Numbers

GSE88822



# CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in *BRCA* Wild-Type and Mutated Models of Triple-Negative Breast Cancer

Shawn F. Johnson,<sup>1</sup> Cristina Cruz,<sup>2,3</sup> Ann Katrin Greifenberg,<sup>4,5</sup> Sofia Dust,<sup>4,5</sup> Daniel G. Stover,<sup>1,6,7</sup> David Chi,<sup>1</sup> Benjamin Primack,<sup>8,9</sup> Shiliang Cao,<sup>1</sup> Andrea J. Bernhardt,<sup>10</sup> Rhiannon Coulson,<sup>11</sup> Jean-Bernard Lazaro,<sup>8</sup> Bose Kochupurakkal,<sup>8</sup> Heather Sun,<sup>12</sup> Christine Unitt,<sup>12</sup> Lisa A. Moreau,<sup>8,9</sup> Kristopher A. Sarosiek,<sup>1</sup> Maurizio Scaltriti,<sup>13</sup> Dejan Juric,<sup>14,15</sup> José Baselga,<sup>13</sup> Andrea L. Richardson,<sup>12,16</sup> Scott J. Rodig,<sup>12</sup> Alan D. D'Andrea,<sup>8,9</sup> Judith Balmaña,<sup>3</sup> Neil Johnson,<sup>10</sup> Matthias Geyer,<sup>4,5</sup> Violeta Serra,<sup>2</sup> Elgene Lim,<sup>1,11,\*</sup> and Geoffrey I. Shapiro<sup>1,7,17,\*</sup>

<sup>1</sup>Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA

<sup>2</sup>Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, 08035 Barcelona, Spain

<sup>3</sup>Medical Oncology Department, Hospital Vall d'Hebron, Vall d'Hebron Institute of Oncology, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain

<sup>4</sup>Department of Structural Immunology, Institute of Innate Immunity, University of Bonn, 53127 Bonn, Germany

<sup>5</sup>Group Physical Biochemistry, Center of Advanced European Studies and Research, 53175 Bonn, Germany

<sup>6</sup>Department of Cell Biology, Harvard Medical School, Boston, MA 02115, USA

<sup>7</sup>Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA

<sup>8</sup>Department of Radiation Oncology and Center for DNA Damage and Repair, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA

<sup>9</sup>Department of Pediatric Oncology, Dana-Farber Cancer Institute, Children's Hospital and Harvard Medical School, Boston, MA 02215, USA

<sup>10</sup>Developmental Therapeutics Program, Fox Chase Cancer Center, Philadelphia, PA 19111, USA

<sup>11</sup>The Kinghorn Cancer Centre, Garvan Institute of Medical Research, St. Vincent's Health Network, Darlinghurst, NSW 2010, Australia

<sup>12</sup>Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA

<sup>13</sup>Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA

<sup>14</sup>Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114, USA

<sup>15</sup>Department of Medicine, Harvard Medical School, Boston, MA 02114, USA

<sup>16</sup>Present address: Department of Pathology, Johns Hopkins Medicine, Baltimore, MD 21287, USA

<sup>17</sup>Lead Contact

\*Correspondence: [e.lim@garvan.org.au](mailto:e.lim@garvan.org.au) (E.L.), [geoffrey\\_shapiro@dfci.harvard.edu](mailto:geoffrey_shapiro@dfci.harvard.edu) (G.I.S.)

<http://dx.doi.org/10.1016/j.celrep.2016.10.077>

## SUMMARY

Although poly(ADP-ribose) polymerase (PARP) inhibitors are active in homologous recombination (HR)-deficient cancers, their utility is limited by acquired resistance after restoration of HR. Here, we report that dinaciclib, an inhibitor of cyclin-dependent kinases (CDKs) 1, 2, 5, and 9, additionally has potent activity against CDK12, a transcriptional regulator of HR. In *BRCA*-mutated triple-negative breast cancer (TNBC) cells and patient-derived xenografts (PDXs), dinaciclib ablates restored HR and reverses PARP inhibitor resistance. Additionally, we show that de novo resistance to PARP inhibition in *BRCA1*-mutated cell lines and a PDX derived from a PARP-inhibitor-naïve *BRCA1* carrier is mediated by residual HR and is reversed by CDK12 inhibition. Finally, dinaciclib augments the degree of response in a PARP-inhibitor-sensitive model, converting tumor growth inhibition to durable regression. These results highlight the significance of HR disruption as a therapeutic strategy and support

the broad use of combined CDK12 and PARP inhibition in TNBC.

## INTRODUCTION

Poly(ADP-ribose) polymerase (PARP) inhibition has emerged as a compelling strategy for *BRCA*-deficient or otherwise homologous recombination (HR)-repair-deficient cancers (Scott et al., 2015). However, the broad utility of these drugs has been limited by their lack of activity in HR-proficient cancers, as well as acquired resistance of initially responding tumors, often mediated by restoration of HR (Bouwman and Jonkers, 2014). Additionally, a proportion of *BRCA*-mutated cancers display de novo (primary) resistance, potentially mediated by hypomorphic isoforms of *BRCA1* (Hill et al., 2014), tumor heterozygosity (King et al., 2007), or preexisting alterations in the DNA damage response that may confer residual HR activity (Bouwman et al., 2010).

These challenges have prompted interest in combining PARP inhibitors with agents capable of disrupting HR in cancer cells as an approach to sensitize *BRCA* wild-type cancers to PARP inhibition, and also to overcome de novo and acquired resistance in *BRCA*-mutated cancers. Because complex mechanisms of HR restoration confer resistance to PARP inhibitors in

*BRCA*-mutated cells, simultaneous suppression of multiple HR genes together with PARP inhibition may be a preferred strategy for resensitizing resistant cells to these agents. In this regard, cyclin-dependent kinase (CDK) 12, an RNA polymerase II C-terminal domain (CTD) kinase, has recently been identified as an essential regulator for the transcription of various DNA damage response (DDR) and DNA repair genes, particularly those involved in the HR and Fanconi anemia (FA) pathways (Bartkowiak et al., 2010; Blazek et al., 2011; Liang et al., 2015). Somatic inactivating mutations in CDK12 have been observed in a subset of epithelial ovarian carcinomas, resulting in compromised HR (Joshi et al., 2014). Furthermore, short hairpin RNA (shRNA)-mediated depletion of CDK12, or its cyclin K binding partner, from *BRCA* and *CDK12* wild-type ovarian cancer or other transformed cell lines has been shown to suppress HR gene expression and sensitize cells to cisplatin-induced interstrand cross-links and PARP inhibition (Bajrami et al., 2014; Blazek et al., 2011; Joshi et al., 2014).

These observations have led to interest in the development of pharmacological inhibitors of CDK12 to act as sensitizers to PARP inhibitors, as well as to standard DNA-damaging agents. Here, we show that dinaciclib, a known inhibitor of CDKs 1, 2, 5, and 9 (Parry et al., 2010) that has produced documented responses in breast cancer (Mita et al., 2014), has previously unreported potent activity against CDK12. We studied dinaciclib as a CDK12 inhibitor in models of triple-negative breast cancer (TNBC), an aggressive breast cancer subset associated with poor outcome and absence of defined molecular targets. Dinaciclib reduces HR gene expression in *BRCA* wild-type TNBC cells and sensitizes these cells to PARP inhibition. We have further investigated the activity of dinaciclib in concert with PARP inhibition in *BRCA*-mutated TNBC cell lines and patient-derived xenograft (PDX) models, and demonstrate reversal of de novo and acquired PARP inhibitor resistance. Finally, in a *BRCA*-mutated model in which long-term tumor growth control is achieved by PARP inhibitor monotherapy, the addition of dinaciclib converts the outcome to deep and prolonged tumor regression. Collectively, these data support the combination of dinaciclib with PARP inhibition in both *BRCA* wild-type and mutant TNBCs.

## RESULTS

### Dinaciclib Inhibits CDK12 with Greater Potency Than Other Known Transcriptional CDK Inhibitors


To identify potential inhibitors of CDK12, we made use of its recently elucidated crystal structure. Although the kinase domain of CDK12 shares significant primary sequence homology with CDK9, a panel of small-molecule CDK9 inhibitors was previously shown to have substantially reduced potency against CDK12 in *in vitro* biochemical assays (Bösken et al., 2014). To further interrogate this result, we aligned the CDK12 crystal structure 4NST with the CDK9 crystal structure 3BLQ (Baumli et al., 2008). Although the two kinases share extensive tertiary structural homology (root-mean-square deviation [RMSD] = 0.83 Å; Figure 1A), inspection of secondary structure elements demonstrated a variance in the C-terminal portion of each kinase domain (Figures 1B and S1A). CDKs that regulate transcriptional elongation have a unique extension helix that lies C-terminal to

the canonical CDK kinase domain. In CDK12, this extension helix interacts with the ATP binding site and is initiated by a DCHEL motif beginning at amino acid 1038. The interaction of the C-terminal extension helix with the nucleotide binding site of CDK12 is mediated by the H1040 and E1041 residues, and loss of the helix severely disrupts activity of the kinase (Bösken et al., 2014). CDK9 shares a similar C-terminal extension helix, but does not share the initiating <sup>1038</sup>DCHEL motif (Figure 1B). Because this structural variation occurs in close proximity to the site of binding for small-molecule inhibitors of CDK9, we hypothesized that it may be responsible for the lack of shared specificity with CDK12. *In silico* modeling of flavopiridol, a well-described potent CDK9 inhibitor, into the ATP binding site of CDK12 revealed a significant steric clash between the benzene ring of bound flavopiridol and the H1040 residue of the DCHEL motif of CDK12. To determine whether this occlusion was a shared feature of other compounds that tightly bind CDK9, we modeled dinaciclib, a CDK9 inhibitor that had not been tested against CDK12, into the CDK12 ATP binding site. In contrast with flavopiridol, there does not appear to be steric hindrance between the CDK12 H1040 aromatic ring and the pyridine-*N*-oxide ring of dinaciclib (Figure 1B).

We predicted that this favorable interaction would afford potent CDK12 inhibitory activity to dinaciclib. The addition of 10× or 1,000× concentration of dinaciclib to 0.2 μM cyclin K-CDK12 or cyclin T-CDK9 holoenzyme complexes reduced CDK12 activity by approximately 20-fold and CDK9 activity by 12- to 25-fold (Figure 1C). Compared with previously reported results of similar assays using other CDK9 inhibitors (Bösken et al., 2014), dinaciclib demonstrates strong inhibition of CDK12 kinase activity. Concentration series were then performed to determine half-maximal inhibitory concentration (IC<sub>50</sub>) values against CDK12 and other CDK family members (Figures 1D and S1B). Whereas flavopiridol had only modest activity against CDK12 with potency compared with CDK9 reduced by more than 10-fold (Bösken et al., 2014), dinaciclib demonstrated robust inhibitory activity against both kinases, with IC<sub>50</sub> in the 40–60 nM range, making it the most potent known inhibitor of CDK12. Furthermore, mutation of the H1040 site to glycine, or mutation of either the DCHEL motif or the adjacent polybasic region to alanine conferred sensitivity of CDK12 to flavopiridol, consistent with the predictions of structural modeling. In contrast, these three CDK12 mutations had no effect on the IC<sub>50</sub> of dinaciclib (Figure 1D).

### Dinaciclib Displays Hallmarks of CDK12 Inhibition in *BRCA* Wild-Type TNBC Cells

We next characterized the transcriptional effects of dinaciclib treatment on TNBC cells. Eukaryotic gene transcription is regulated by a coordinated sequence of phosphorylation events along the CTD of RNA polymerase II. CDK9 is recruited to the 5' ends of gene bodies, where it primarily phosphorylates CTD-Ser5, releasing the assembled transcription complex from promoter-proximal pausing and initiating transcription (Eick and Geyer, 2013; Ghamari et al., 2013). CDK12 is predominantly associated with the 3' ends of genes, where it has been shown to coordinate transcript elongation and processing largely by phosphorylation of CTD-Ser2 (Bartkowiak et al., 2010; Blazek et al.,



**Figure 1. Dinaciclib Is a Potent Inhibitor of CDK12 in Addition to CDK9**

(A) Tertiary structural alignment of CDK9 and CDK12.

(B) Sequence corresponding to the variance in the C-terminal extension helix of the kinase domains of CDK12 and CDK9 (see also Figure S1), as well as structural modeling of the orientations of flavopiridol and dinaciclib in relation to H1040 and E1041 of the CDK12 ATP binding site. The benzene ring of flavopiridol shows a steric clash with H1040 of CDK12, whereas the pyridine-*N*-oxide ring of dinaciclib overlaps the aromatic H1040 side chain, resulting in a possible stacking of the aromatic ring systems that stabilizes the interaction and contributes to binding specificity.

(C) In vitro kinase assays using pS7-CTD<sub>[3]</sub> as substrate and 0.2 μM cyclin T-CDK9 and cyclin K-CDK12 holoenzyme complexes alone or with 10× or 1,000× dinaciclib.

(D) Concentration series of dinaciclib and flavopiridol for cyclin T1-CDK9 and cyclin K-CDK12 at 0.2 μM kinase concentration. The IC<sub>50</sub> values against CDK9 and CDK12 are comparable for dinaciclib, but disparate for flavopiridol. Introduction of the indicated mutations sensitizes CDK12 to flavopiridol. All data are reported as the mean ± SD from three independent experiments.

2011; Eick and Geyer, 2013). Treatment of MDA-MB-231 cells with low nanomolar concentrations of dinaciclib for 6 hr resulted in concentration-dependent reduction in phospho-CTD levels, with greater effects on Ser2 compared with Ser5 phosphorylation (Figure 2A).

Whereas CDK9-mediated phosphorylation of RNA polymerase II occurs globally across transcripts (Garriga and Graña, 2004), CDK12 predominantly associates with the 3' ends of genes involved with DNA damage and repair (Blazek et al., 2011). Gene expression analysis of RNA collected from MDA-MB-231 cells after 12 hr of dinaciclib exposure showed a significant reduction in expression of only a limited number of genes, in contrast with the global transcriptional repression that has been reported with potent CDK9 inhibitors (Lam et al., 2001) (Figure 2B). Pathway analysis revealed that the differentially expressed genes were significantly enriched for those involved in HR repair and DNA damage-sensing (Figures 2C and S2A), with representation from multiple genes previously reported to be repressed by disruption of CDK12 activity (Blazek et al., 2011) (Figure 2D). We confirmed these results via qPCR using primers for *BRCA1* and *RAD51* (Figure 2E). Consequently, the expression of multiple proteins involved in HR was decreased in dinaciclib-treated cells, demonstrated in both concentration- and time-dependent experiments, with substantial reduction of these proteins by 24 hr (Figures 2F and 2G). Importantly, the transcriptional effects of dinaciclib could not be attributed to a block in cell cycle progression, because we observed only minimal cell cycle perturbations in asynchronous or hydroxyurea-synchronized cells (Figures 2H and S2B). Taken together, these data suggest that dinaciclib acts primarily as a transcriptional CDK inhibitor in TNBC cells, and that the transcriptional consequences of dinaciclib exposure are predominantly associated with its inhibition of CDK12.

### Dinaciclib Compromises HR Repair and Sensitizes BRCA Wild-Type TNBC Cells to PARP Inhibition

We reasoned that the transcriptional effects of dinaciclib that we observed would severely impair HR, as reported in multiple myeloma cells (Alagpulinsa et al., 2016). To test this prediction, we assessed functional metrics of HR in *BRCA* wild-type TNBC cells. Irradiated MDA-MB-231 cells pretreated with dinaciclib showed significant concentration-dependent reduction in the recruitment of *BRCA1* and *RAD51* to sites of double-strand DNA breaks (Figures 3A and 3B). To directly measure HR, we utilized U2OS cells with stable integration of the DR-GFP reporter. Transfection of the I-SceI restriction enzyme resulted in 13.3% and 3.6% GFP-positive cells following vehicle or dinaciclib treatment, respectively (Figures 3C and S3A). The profound disruption of HR suggested that dinaciclib could sensitize HR-proficient cells to PARP inhibition. We found that dinaciclib treatment sensitized a panel of *BRCA* wild-type TNBC cell lines to the PARP inhibitor veliparib (Figures 3D and S3B). In the presence of dinaciclib, the IC<sub>50</sub> to veliparib was reduced between 2.5- and 12.5-fold (Table S1).

### Effects of Dinaciclib in TNBC Cells Are Phenocopied by CDK12 Knockout

To provide further evidence that the effects of dinaciclib are mediated by CDK12 inhibition, we utilized CRISPR/Cas9-mediated


knockout of CDK12 in MDA-MB-468 and BT549 cells (Figure S4A). Knockout of CDK12 caused reduced expression of *BRCA1*, *BRCA2*, and *RAD51*, which compromised *RAD51* focus formation after  $\gamma$ -irradiation, and resulted in substantial sensitization to veliparib. Importantly, treatment with dinaciclib did not further sensitize CDK12-depleted cells to veliparib. CDK9 knockout did not reduce HR gene expression (Figure S4A). Consistent with previously published results, CDK9 knockout over several days was lethal to TNBC cells (Wang et al., 2015). We therefore used low concentrations of flavopiridol (Figure S4B), which reduced phosphorylation of Ser5, but not Ser2, of the CTD, and we observed no impact on HR gene expression or *RAD51* focus formation after DNA damage. In contrast with dinaciclib or CDK12 knockout, flavopiridol did not sensitize TNBC cells to veliparib- or olaparib-mediated PARP inhibition.

### BRCA Mutant TNBC Cells with Acquired PARP Inhibitor Resistance Are Resensitized to PARP Inhibition by Dinaciclib

Many mechanisms of acquired PARP inhibitor resistance have shared a common feature in that they restore *RAD51* loading and rescue HR repair. We hypothesized that the multifocal disruption of HR resulting from CDK12 inhibition could potentially resensitize *BRCA*-mutated cells that have developed resistance to PARP inhibition. We made use of a previously generated PARP-inhibitor-resistant clone of the *BRCA1*-mutated MDA-MB-436 cell line, in which heterozygous mutation of the *TP53BP1* gene and stabilization of a hypomorphic BRCT-domain-mutated *BRCA1* protein results in rescue of DNA end resection, *RAD51* loading, and HR (Johnson et al., 2013). Dinaciclib treatment substantially reduced protein levels of both *RAD51* and the hypomorphic *BRCA1* mutant protein, as well as formation of *RAD51* foci following irradiation, and resensitized the resistant cells to PARP inhibition (Figure 3E; Table S1).

To test the ability of dinaciclib to reverse acquired PARP inhibitor resistance *in vivo*, we generated a PDX model derived from a TNBC patient carrying a germline S1970\* *BRCA2* mutation. This heavily pretreated patient achieved stable disease for approximately 10 months on combined cisplatin and olaparib followed by olaparib alone (Balmaña et al., 2014), before disease progression. After brief intervening chemotherapy, a biopsy was performed when new hepatic metastases developed, which was used for establishment of the PDX 12-58 model (Figure 3F) (Tao et al., 2014). Although targeted sequencing did not demonstrate evidence of a *BRCA2* reversion mutation (Figure S5A), the model was refractory to cisplatin as well as veliparib (Figures 3G and 3H), requiring animal euthanasia at approximately 40 days for progressive tumor growth, suggesting alternative mechanisms governing resistance. However, the combination of dinaciclib and veliparib resulted in tumor growth inhibition lasting at least 60 days (Figure 3H). End-of-experiment histology revealed no abnormalities in lung, liver, gastrointestinal (GI) tract, and bone marrow of combination-treated mice, with similar appearance of organs harvested from vehicle-treated mice and only modest staining for gamma-H2AX ( $\gamma$ -H2AX) in marrow (Figure S5B).

To further study the selectivity of combination treatment for transformed cells, we exposed human mammary epithelial cells



**Figure 2. Dinaciclib Is a Transcriptional CDK Inhibitor That Reduces Expression of Genes in DNA Damage Response and DNA Repair Pathways**

(A) MDA-MB-231 cells were treated with the indicated concentrations of dinaciclib for 6 hr, demonstrating reduced phosphorylation at the Ser2 and Ser5 sites of the CTD of RNA polymerase II.

(B) Cells were collected before and after treatment with 10 nM dinaciclib for 12 hr, and changes in transcription were measured using the Affymetrix HG-U133A2 arrays. Analyses were performed in triplicate. Twenty-one percent of genes were significantly downregulated in dinaciclib-treated versus untreated samples ( $p < 0.05$ ).

(C) Genes statistically significantly downregulated in response to dinaciclib were analyzed by Ingenuity Pathway Analysis (IPA) software, demonstrating downregulation of DNA damage response and DNA repair pathways.


(D) Expression of genes in the “role of BRCA1 in DNA damage response” pathway.

(E) Downregulation of expression of *BRCA1* and *RAD51* mRNAs in cells treated with the indicated concentrations of dinaciclib was confirmed utilizing RT-PCR.

(F) Concentration-dependent reduction in expression of *BRCA1*, *BRCA2*, *RAD51*, and *FANCD2* in cells treated with dinaciclib for 24 hr.

(G) Time-dependent reduction in expression of *BRCA1* and *RAD51* in response to dinaciclib.

(H) Cell cycle patterns following dinaciclib exposure demonstrate the absence of G1 arrest in MDA-MB-231 cells (see also Figure S2).



(legend on next page)

(HMECs) to olaparib in the absence or presence of dinaciclib (Figure S5C). In contrast with transformed cells, dinaciclib improved the viability of HMECs treated with olaparib; this protective effect was likely due to the much greater degree of G2 arrest observed, which should preclude PARP-inhibitor-mediated cytotoxicity that typically occurs in S phase.

### Characterization of *BRCA1*-Mutated TNBC Cells with De Novo PARP Inhibitor Resistance

In addition to acquired PARP inhibitor resistance, there is a high rate of de novo resistance to PARP inhibition in *BRCA*-mutated tumors. To address the utility of CDK12 inhibition in this setting, we first identified and characterized *BRCA*-mutated cell lines with primary PARP inhibitor resistance. Relative PARP inhibitor sensitivity was determined for a panel of *BRCA1*-mutated TNBC cell lines using hormone-receptor-positive and non-transformed breast cell lines as a reference standard for insensitivity to PARP inhibition. Whereas MDA-MB-436 and HCC1395 displayed exquisite sensitivity to PARP inhibition, SUM149 and HCC1937 were relatively insensitive to PARP inhibitor treatment, either with veliparib or with olaparib (Figures 4A and S6A). To determine whether the variability in sensitivity to PARP inhibition was due to differences in susceptibility to apoptosis, we performed mitochondrial BH3 profiling on the *BRCA*-mutated cell lines. No significant differences were observed (Figure S7), suggesting that resistance to PARP inhibition in SUM149PT and HCC1937 was not due to an anti-apoptotic phenotype.

In addition to PARP inhibition, HR-deficient tumors are sensitive to the accumulation of DNA interstrand crosslinks (ICLs). To our surprise, all four *BRCA1*-mutated cell lines displayed marked sensitivity to cisplatin, regardless of PARP inhibitor sensitivity (Figure 4A). Furthermore, we observed that treatment with another DNA crosslinking agent, mitomycin C, resulted in accumulation of chromosomal aberrations in both PARP-inhibitor-resistant and -sensitive *BRCA1*-mutated lines, whereas veliparib produced chromosomal aberrations in only MDA-MB-436 and HCC1395 cells (Figure 4B).

While sensitivity to PARP inhibition is associated with defects in HR, the repair of ICLs requires the activity of multiple DNA repair pathways, including nucleotide excision repair (NER) and

the Fanconi anemia (FA) pathway, in addition to HR. *BRCA1* function is essential for both HR and the FA pathway, and *BRCA1*-deficient tumors have been observed to also carry NER defects. We hypothesized that the *BRCA1*-mutated cell lines SUM149PT and HCC1937 may have selectively retained functional HR while maintaining a defect in NER, as described for a subset of *BRCA1*-mutated ovarian carcinomas (Ceccaldi et al., 2015), or the FA pathway, as in *Brca1*<sup>-/-</sup> *53BP1*<sup>-/-</sup> mouse embryonic fibroblasts (MEFs) that display resistance to PARP inhibition, but sensitivity to crosslinking agents (Bunting et al., 2012).

We first assessed NER proficiency in SUM149 and HCC1937, and failed to detect an NER defect in either cell line (Figure S6B). We next determined HR and FA pathway proficiency by monitoring the recruitment of repair factors immediately downstream of *BRCA1* in both pathways. Recent work has demonstrated that, in addition to its role in RAD51 loading following end resection in HR, *BRCA1* is required for the removal of stalled replication machinery and subsequent recruitment of the FA complex to the site of crosslinks (Schlachter et al., 2012). We therefore measured RAD51 and FANCD2 foci formation as surrogate markers for repair activity downstream of the role of *BRCA1* in the HR and FA pathways, respectively (Figure 4D). Following PARP inhibitor treatment, a significant increase in RAD51 foci was observed in SUM149PT and HCC1937, suggesting the presence of functional HR. Strikingly, none of the *BRCA1*-mutated lines displayed recruitment of FANCD2 foci following cisplatin treatment. These data suggest that similar to the phenotype observed in MEF genetic studies (Bunting et al., 2012), human pathogenic mutations in *BRCA1* may affect separate DNA repair pathways to varying extents.

### SUM149PT and HCC1937 Cells Require *BRCA* Proteins for HR, which Can Be Depleted by Dinaciclib

We next sought to determine pathway components necessary for the residual HR function of SUM149PT and HCC1937 cells and whether removal of these factors would result in sensitization to PARP inhibition. SUM149PT cells carry a 2288delT mutation in exon 11 of *BRCA1*, resulting in loss of the full-length p220 isoform of *BRCA1* but detectable levels of a truncated

### Figure 3. Disruption of HR by Dinaciclib and Sensitization to PARP Inhibition of *BRCA* Wild-Type and *BRCA*-Mutated Cells with Acquired PARP Inhibitor Resistance

(A) Cells were treated with vehicle or 10 nM dinaciclib for 18 hr prior to treatment with 10 Gy  $\gamma$ -irradiation (IR). Six hours post-IR, cells were analyzed for *BRCA1*, RAD51, and  $\gamma$ -H2AX focus formation.

(B) Quantification of cells with more than five foci in irradiated cells pretreated with vehicle or dinaciclib at the indicated concentrations.

(C) U2OS DR-GFP cells were transfected with I-SceI in the presence of vehicle or 15 nM dinaciclib. The percentage of GFP-positive cells is significantly reduced ( $p < 0.0001$ ) in the presence of dinaciclib, consistent with direct inhibition of HR repair (see also Figure S3).

(D) *BRCA*-proficient TNBC cell lines were treated with veliparib in the absence or presence of dinaciclib, demonstrating reduced IC<sub>50</sub> values in the presence of dinaciclib.

(E) An MDA-MB-436 PARP-inhibitor-resistant derivative (MDA-MB-436-RR2) (Johnson et al., 2013) was treated with veliparib in the absence or presence of dinaciclib, demonstrating reduced IC<sub>50</sub> in the presence of dinaciclib (left). Reduced expression of the mutant *BRCA1* protein and RAD51 in response to dinaciclib (middle). MDA-MB-436-RR2 cells were treated with vehicle or dinaciclib at the indicated concentration for 18 hr, subjected to 10 Gy IR, and assessed for RAD51 focus formation 6 hr later (right);  $p < 0.0001$ . All data in (B)–(E) are reported as mean  $\pm$  SD for a minimum of three independent experiments.


(F) Treatment history of the *BRCA2* carrier; PDX 12-58 was procured after progression on cisplatin and olaparib (see also Figure S4A).

(G) Mice bearing 12-58 xenografts were treated with vehicle ( $n = 3$ ) or cisplatin ( $n = 3$ ) on days 1 and 22 (arrows), with tumor volume measured over 36 days.

(H) Mice were treated with vehicle ( $n = 4$ ), veliparib ( $n = 8$ ), dinaciclib ( $n = 8$ ), or the combination ( $n = 8$ ). Combination treatment produced significant tumor growth inhibition at day 42 compared with vehicle ( $p < 0.0001$ ) or monotherapies ( $p < 0.0001$  for both veliparib and dinaciclib).

\* $p < 0.01$ , \*\* $p \leq 0.001$ , \*\*\* $p \leq 0.0001$  for experimental value versus control. SD, stable disease. In (G) and (H), data are reported as mean  $\pm$  SEM.





**Figure 4. Characterization of BRCA1-Mutated TNBC Cell Lines**


(A) Panel of indicated cell lines was treated with veliparib or cisplatin over a range of concentrations and viability was assessed after 7 days of treatment. (B) Cells were treated with vehicle, veliparib, or mitomycin C, and metaphase spreads were prepared; radials quantified in vehicle- and drug-treated cells. (C) Cells were treated with vehicle, veliparib, or cisplatin and analyzed by immunofluorescence for RAD51 and FANCD2 foci. Graphs show quantification of cells with more than five foci in vehicle- and drug-treated cells. Data in (A) and (C) are reported as the mean  $\pm$  SD for a minimum of three independent experiments.

BRCA1 $\Delta$ 672-4095 isoform, BRCA1  $\Delta$ 11b, produced from an in-frame splicing event that removes exon 11 (Hill et al., 2014). We hypothesized that the BRCA1  $\Delta$ 11b isoform, which retains the C-terminal BRCT domains necessary for RAD51 loading, may facilitate HR and confer PARP inhibitor resistance. Small interfering RNA (siRNA)-mediated depletion of BRCA1  $\Delta$ 11b resulted in sensitization of SUM149PT to PARP inhibition (Figure 5A). Additionally, we observed that siRNA targeting of either BRCA2 or PALB2 also sensitized SUM149PT to PARP inhibition, suggesting that the  $\Delta$ 11 isoform functions in place of p220 in the BRCA1-PALB2-BRCA2 axis. While the 5382insC BRCA1 mutation in HCC1937 cells ablates expression of both p220 and  $\Delta$ 11b BRCA1 isoforms, we observed a similar sensitization to PARP inhibition following siRNA-mediated depletion of both BRCA2 and PALB2 (Figure 5B).

Based on these observations, we hypothesized that CDK12 inhibition could additionally sensitize PARP-inhibitor-naive BRCA1-mutated cells to PARP inhibition. Dinaciclib treatment resulted in a concentration-dependent reduction of BRCA2, RAD51, and BRCA1  $\Delta$ 11b protein levels (Figure 5C), as well as a reduction in RAD51 foci following  $\gamma$ -irradiation (IR) (Figures 5D and 5E). Additionally, dinaciclib treatment sensitized both SUM149PT and HCC1937 cells to PARP inhibition (Figure 5F; Table S1).

**A 185delAG BRCA1-Mutated PDX Model Demonstrates Cisplatin Sensitivity and Primary PARP Inhibitor Resistance with Residual HR Activity That Is Ablated by Dinaciclib**

The significance of residual HR function as a mechanism of primary resistance to PARP inhibition has not been clarified



**Figure 5. BRCA1-Mutated SUM149PT and HCC1937 Cells Are Sensitized to PARP Inhibition by siRNA- or Dinacliclib-Mediated Depletion of the BRCA1-PALB2-BRCA2 Axis and RAD51**

(A) SUM149PT cells were transfected with the indicated siRNAs targeting BRCA1, BRCA2, or PALB2, followed by veliparib treatment at the indicated concentrations. Viability was assessed by CellTiter-Glo after seven days.

(B) Similar experiments were performed with HCC1937 cells using siRNAs targeting BRCA2 or PALB2.


(C) Cells were treated with vehicle (0 nM) or the indicated concentrations of dinacliclib for 24 hr and nuclear lysates subjected to western blotting with the indicated antibodies.

(D) Cells were pretreated with vehicle or 10 nM dinacliclib for 18 hr followed by 10 Gy IR. RAD51 and  $\gamma$ -H2AX focus formation was assessed by immunofluorescence 6 hr after IR.

(E) Quantification of RAD51 focus formation 6 hr after IR in cells pretreated with vehicle (0 nM) or the indicated concentrations of dinacliclib ( $p < 0.0001$  for dinacliclib versus vehicle).

(F) Cells were treated with the indicated concentrations of veliparib in the absence or presence of dinacliclib, demonstrating reduced  $IC_{50}$  values in the presence of dinacliclib.

All data are reported as the mean  $\pm$  SD for a minimum of three independent experiments.



**Figure 6. Generation and Treatment of the PDX 127 Model from a 185delAG BRCA1 Carrier**

(A) Treatment history of the BRCA1 carrier; the model was procured prior to exposure to cisplatin and olaparib or olaparib monotherapy. PD, progressive disease; PR, partial response.

(B) Mice bearing xenografts were treated with vehicle (n = 4) or cisplatin (n = 6) on the days 1 and 34 (arrows) demonstrating tumor regression in response to platinum-based treatment.

(C) Mice bearing xenografts were treated with vehicle (n = 8), olaparib (n = 7), dinaciclib (n = 3), or the combination (n = 7). Combination treatment produced significant tumor growth inhibition compared with vehicle or monotherapies. At day 35, \*p = 0.018 for combination versus dinaciclib and \*\*p < 0.0001 for combination versus olaparib.

(legend continued on next page)

because of the limited availability of clinical samples. To address this issue, we established a xenograft model (PDX 127) from a PARP-inhibitor-naive germline 185delAG *BRCA1* carrier presenting with metastatic TNBC (Figure 6A). The patient received cisplatin and olaparib in combination. After experiencing a partial response (PR; ~60% tumor regression) at a dosage of 60 mg/m<sup>2</sup> cisplatin and 50 mg twice-daily olaparib, the patient's course was complicated by cisplatin-associated peripheral neuropathy, prompting a transition to 400 mg twice-daily olaparib monotherapy, on which the patient experienced rapid disease progression. Based on the observation that the patient's PR had occurred on a suboptimal dose of olaparib, we hypothesized that her disease may have possessed a platinum-sensitive/PARP-inhibitor-resistant phenotype similar to SUM149PT and HCC1937. Because the biopsy utilized for generation of the PDX model was procured prior to receiving cisplatin and olaparib in combination, we were able to address this question in vivo. Cisplatin treatment of PDX 127 resulted in tumor regression (Figure 6B), whereas olaparib monotherapy demonstrated minimal tumor growth inhibition (Figure 6C). Whole exome sequencing of the PDX 127 model ruled out *BRCA1* reversion mutation as a cause of PARP inhibitor resistance (Figure S5A). Tumor samples taken from vehicle- and olaparib-treated PDX 127-bearing mice demonstrated the formation of RAD51 foci following olaparib treatment, supporting our hypothesis that preservation of HR function had resulted in PARP inhibitor resistance (Figure 6D).

We next sought to determine whether the combination of dinaciclib and olaparib could be extended to this model of primary PARP inhibitor resistance. Treatment with dinaciclib resulted in reduced HR gene mRNA and protein expression (Figures 6E and 6F) in the absence of evidence of cycle arrest (Figure S5D); as a result, the formation of RAD51 foci in response to olaparib treatment was significantly suppressed in the combination-treated mice. Tumors treated with the combination also displayed significantly greater induction of  $\gamma$ -H2AX foci compared with those treated with olaparib or dinaciclib alone (Figure 6D). These effects translated to prolonged disease stabilization in mice treated with the combination (Figure 6C). These results provide evidence for the role of residual HR as a mechanism of resistance in PARP-inhibitor-naive *BRCA1* mutant human tumors and suggest that combining a CDK12 inhibitor with a PARP inhibitor may be an effective treatment strategy in this setting.

#### Activity of Combined CDK12 and PARP Inhibition in a Model with Initial PARP Inhibitor Sensitivity

Although many *BRCA1/2*-mutated tumors display initial sensitivity to PARP inhibition, treatment in the metastatic setting is not curative, and clinical benefit is manifested by transient and incomplete

tumor regressions or sustained stable disease. We established an additional PDX model (11-26) from a patient with early-stage TNBC harboring a somatic *BRCA1* R1443\* mutation. Consistent with HR deficiency, although the PDX model expressed RAD51, foci were not observed after short-term exposure to PARP inhibition (Figures 7A and 7B). As expected, dinaciclib reduced RAD51 expression (Figure 7B) not attributable to cell cycle arrest (Figure S5D).

PARP inhibitor monotherapy produced stable disease over a prolonged 156-day time course, although palpable primary tumors were detectable for the duration of the experiment. The addition of dinaciclib to veliparib resulted in substantial and durable tumor regression (Figures 7C and 7D).

Immunohistochemistry performed on tumors harvested at the end of the experiment demonstrated viable cell populations in vehicle- and monotherapy-treated tumors (Figure 7E). In contrast, bland fibrous tissue predominated in combination-treated tumors; small nests of tumor cells were present, which displayed expression of  $\gamma$ -H2AX, consistent with the induction of persistent DNA damage (Figures 7E and 7F). Finally, histological analyses of liver, lung, GI tract, and bone marrow harvested at the end of experiment from combination-treated mice revealed no abnormalities, with only minimal  $\gamma$ -H2AX staining, indicating that the combination of dinaciclib and veliparib was tolerable to normal tissues over a prolonged treatment course (Figure S5B). These data suggest that the addition of dinaciclib to PARP inhibition can augment the quality and degree of response, even in a tumor initially susceptible to PARP inhibitor monotherapy.

## DISCUSSION

The development of PARP inhibitor resistance in *BRCA*-mutated cancers is a pressing clinical problem. Restoration of HR plays a major role in acquired resistance and may occur by varied and complex mechanisms, highlighting the need for a therapeutic strategy that can be broadly applied across patients with tumors resistant to PARP inhibitors. Here, we demonstrate that the combination of CDK12 and PARP inhibition represents a viable approach for reversing such resistance.

In the MDA-MB-436 BRCT domain *BRCA1* mutant derivatives with acquired PARP inhibitor resistance, RAD51 loading is facilitated by an HSP90-stabilized splice variant mutant *BRCA1* (Johnson et al., 2013). Because transcription of the *BRCA1* splice variant is driven by the intact *BRCA1* promoter, inhibition of CDK12 is expected to reduce its expression. Dinaciclib ablated expression of the mutant protein, inhibited HR, and re-established PARP inhibitor sensitivity.


The multiple components of the HR pathway that are transcriptionally downregulated by CDK12 inhibition suggest that this

(D) Mice bearing xenografts were treated with vehicle, olaparib, dinaciclib, or the combination (n = 6/group). (Left) After 15 days, mice were sacrificed and tumors subjected to immunofluorescence for RAD51 and  $\gamma$ -H2AX foci. (Right) Quantification of cells with more than five  $\gamma$ -H2AX foci, as well as  $\gamma$ -H2AX-positive cells with more than five RAD51 foci. For  $\gamma$ -H2AX foci, p = 0.103, \*p = 0.013, and p = 0.005 for control versus dinaciclib, olaparib, or the combination, respectively. p < 0.0001 and \*\*p < 0.0076 for dinaciclib or olaparib versus the combination, respectively. For RAD51 quantification in  $\gamma$ -H2AX-positive cells, p = 0.69, p = 0.04, and p = 0.74 (non-significant [NS]) for control versus dinaciclib, olaparib, or the combination, respectively. p = 0.158 and \*\*p = 0.0035 for dinaciclib or olaparib versus the combination, respectively.

All data in (B)–(D) are reported as mean  $\pm$  SEM.

(E) Tumor RNA from mice in (D) treated with vehicle or dinaciclib (n = 3/group) was subjected to RT-PCR for *BRCA1* and RAD51. \*\*p = 0.000068 for vehicle versus dinaciclib in both cases. Data are reported as the mean  $\pm$  SD.

(F) Tumor lysates from mice in (D) treated with vehicle or dinaciclib were subjected to western blotting with the indicated antibodies.



**Figure 7. Treatment of the 11-26 PDX Model Harboring Somatic *BRCA1* R1443\* Mutation**

(A) Mice bearing xenografts were treated with vehicle or veliparib ( $n = 5/\text{group}$ ). (Left) After 15 days, mice were sacrificed and tumors subjected to immunofluorescence for RAD51 and  $\gamma$ -H2AX foci. (Right) Quantification of  $\gamma$ -H2AX-positive cells with more than five RAD51 foci. The  $p$  value is non-significant.

(B) Mice bearing xenografts were treated with vehicle or dinaciclib for two doses over 5 days ( $n = 3/\text{group}$ ), after which mice were sacrificed and tumors stained for RAD51.  $p = 0.059$ . Scale bar, 100  $\mu\text{m}$ .

(C) Mice bearing xenografts were treated with vehicle ( $n = 3$ ), dinaciclib ( $n = 7$ ), veliparib ( $n = 4$ ), or the combination ( $n = 10$ ), demonstrating long-term growth control with veliparib and sustained tumor regressions with combination treatment. After 2 months of treatment (day 61),  $*p < 0.001$  for combination treatment versus either monotherapy. All data in (A)–(C) are reported as the mean  $\pm$  SEM.

(D) Waterfall plot demonstrating % change in tumor volume at the time of sacrifice for individual mice in the four treatment groups.

(E) Representative end-of-experiment histology (H&E) and  $\gamma$ -H2AX staining of tumors isolated from mice in the four treatment groups. Scale bar, 100  $\mu\text{m}$ .

(F) Quantification of % nuclei staining positively for  $\gamma$ -H2AX at end of experiment ( $*p < 0.05$  for combination versus control treatment). Data are reported as the mean  $\pm$  SD from a minimum of four xenografts/group.

strategy may be effective even when the precise mechanism of HR restoration is unknown. In the PDX model of acquired PARP inhibitor resistance (12–58), a *BRCA2* reversion was not detected, and the events underlying PARP inhibitor and platinum resistance

are under further investigation. Nonetheless, tumor growth inhibition was imposed by combined dinaciclib and PARP inhibition.

Hypomorphic *BRCA1* proteins may account for some instances of de novo PARP inhibitor resistance, illustrated by

mutations arising in exon 11 of the *BRCA1* reading frame. Consequently, *BRCA1*  $\Delta$ 11b-expressing SUM149PT cells exhibit primary PARP inhibitor resistance that may be reversed by siRNA- or CDK12 inhibitor-mediated depletion of the hypomorphic protein or other components of the *BRCA1*-*PALB2*-*BRCA2* axis. In a second *BRCA1*-mutated cell line, HCC1937 (*BRCA1* 5382insC), PARP inhibitor resistance is *BRCA1* independent, possibly related to a compensatory role for *RAD52* (Lok et al., 2013). HCC1937 cells continue to be dependent on remaining components of the *BRCA1*-*PALB2*-*BRCA2* axis, allowing them to be similarly sensitized to PARP inhibition by dinaciclib treatment. Additionally, the existence and clinical significance of residual HR in tumors arising in PARP-inhibitor-naive *BRCA* carriers has remained unknown. Here, we show evidence of residual HR in the clinical course of a 185delAG *BRCA1* carrier, whose tumor was resistant to olaparib, but sensitized with dinaciclib.

Despite exhibiting PARP inhibitor resistance, SUM149PT and HCC1937 cells, as well as the PDX 127 model, demonstrated sensitivity to cisplatin. The retention of residual HR in these models is not adequate to confer FA pathway proficiency, which is required for the repair of damage induced by DNA crosslinking agents. These results further emphasize that PARP inhibitor and platinum sensitivity are not always concordant (Bunting et al., 2012), and provide additional evidence for the importance of platinum agents in *BRCA*-mutated TNBC.

Lastly, our work suggests that combined CDK12 and PARP inhibition is applicable to *BRCA*-deficient breast cancers that are PARP inhibitor susceptible. Regressions in such tumors are rarely complete, and in some cases are short-lived. In the *K14cre;BRCA1<sup>F/F</sup>;p53<sup>F/F</sup>* genetically engineered mouse model challenged with PARP inhibitor monotherapy, not all tumors regress, with some demonstrating stable disease (Rottenberg et al., 2008). Similarly, in sensitive *BRCA*-mutated TNBC PDX models, outcomes frequently demonstrate stable tumor growth inhibition or minor regression, without complete tumor response (Juvekar et al., 2012). Therefore, the 11-26 PDX model derived from a patient with early-stage TNBC harboring somatic *BRCA1* mutation is representative of PARP-inhibitor-sensitive breast cancers and demonstrated prolonged tumor growth inhibition with veliparib monotherapy. The addition of dinaciclib converted the outcome to sustained regression in all of the mice treated, with only minimal residual disease evident on analysis of end-of-treatment histology.

Although dinaciclib inhibits several cell cycle and transcriptional CDKs, the modest effects on cell cycle progression coupled with the transcriptional profile suggest that the phenotype we observed in tumor cells is primarily driven by inhibition of CDK12. The highly potent CDK12 inhibitory activity in biochemical assays distinguishes dinaciclib from all other CDK inhibitors tested that target CDK family members to varying degrees (Bösken et al., 2014). These results have implications for the future development of dinaciclib and suggest that combinatorial strategies including PARP inhibitors or other DNA-damaging agents should be prioritized.

An important requisite of any HR targeting strategy for PARP inhibitor sensitization is selectivity for tumor cells. Dinaciclib-mediated inhibition of cell cycle CDKs appears to arrest mam-

mary epithelial cells in G2/M to a greater degree than TNBC cells. This is expected to impede PARP-inhibitor-mediated cell death that occurs in S phase, affording a favorable therapeutic index. Further work will be required to determine whether concomitant cell cycle CDK inhibition is necessary for the tolerability of combined CDK12 and PARP inhibition. It is also possible that cells with inherent genomic instability may be highly dependent on CDK12-directed transcription to accomplish necessary repair, and therefore particularly vulnerable to reduced CDK12 activity in concert with PARP inhibition, whereas genetically stable non-transformed cells may require only low rates of transcription of such genes and are thus able to tolerate the degree of suppression achieved by reversible kinase inhibition. Whatever the precise mechanism, prolonged exposure to combined dinaciclib and veliparib had no apparent toxicity to normal mouse organs, while achieving profound tumor regression in the 11-26 model.

In summary, dinaciclib is a potent inhibitor of CDK12 that effectively sensitizes *BRCA* wild-type and mutated models of TNBC to PARP inhibition, overcoming primary and acquired resistance. A phase 1 trial of dinaciclib and veliparib is currently in progress (NCT01434316). Once recommended phase 2 doses of the agents are established, the trial will enroll expansion cohorts assessing preliminary activity in both *BRCA* wild-type and *BRCA*-mutated TNBCs.

## EXPERIMENTAL PROCEDURES

### Compounds

Dinaciclib, veliparib, and olaparib were provided by the National Cancer Institute (NCI) Division of Cancer Treatment and Diagnosis (DCTD) or purchased from Selleck Chemicals. Flavopiridol and hydroxyurea were purchased from Enzo Life Sciences and Sigma-Aldrich, respectively.

### In Vitro Kinase Assays

Kinase reactions were carried out using recombinant full-length human CDK9 (1–372) and Cyclin T1 (1–272), and human CDK12 (696–1082) and Cyclin K (1–267), as previously described (Bösken et al., 2014). Measurements were performed in triplicate.

### Cell Lines and Cell Viability Assays

Cell lines were obtained from the American Type Culture Collection. For viability assays, cells were seeded at 500–5,000/well on 96-well plates, cultured in the presence of drugs or vehicle for 7 days, and assessed by CellTiter-Glo (Promega). IC<sub>50</sub> values, determined in the absence or presence of dinaciclib, represent veliparib concentrations at which viability was reduced by 50% of vehicle-treated cells. Cells treated with control siRNAs or those targeting *BRCA1*, *BRCA2*, or *PALB2* were replated in media containing vehicle or veliparib, and viability was determined after 7 days. Mean viability relative to vehicle-treated cells was calculated from a minimum of three experiments.

### Western Blotting

Western blotting was performed with antibodies recognizing *BRCA1* (OP-92; EMD Millipore), *BRCA2* (OP-95; EMD Millipore), *RAD51* (H-92; Santa Cruz Biotechnology), *FANCD2* (NB100-182; Novus Biologicals),  $\gamma$ -H2AX [pS139] (JBW301; EMD Millipore), histone H3 (AB1791; Abcam), CTD [pSer2] (3E10; EMD Millipore), CTD [pSer5] (3E8; EMD Millipore), and total CTD (8WG16; Abcam).

### Gene Expression Array Analysis

MDA-MB-231 cells were treated in triplicate with either vehicle or dinaciclib for 12 hr, and RNA was collected using TRIzol and QIAGEN RNeasy mini kit. Changes in transcription were measured using the Affymetrix HG-U133A2

array platform. Genes statistically significantly downregulated in response to dinaciclib were imported into Ingenuity Pathway Analysis (IPA) software, and networks of these focused genes were built based on the Ingenuity Knowledge Base.

### Establishment and Treatment of Patient-Derived Xenografts

Patient consent for tumor implantation in nude mice was obtained under protocols approved by the IRB of the Dana-Farber/Harvard Cancer Center and the Clinical Investigation Ethical Committee of the Vall D'Hebron University Hospital. Mice were maintained in accordance with local guidelines and therapeutic interventions approved by the Animal Care and Use Committees of Dana-Farber Cancer Institute, Vall D'Hebron Institute of Oncology and the Garvan Institute of Medical Research. TNBC samples were implanted into the cleared fourth mammary fat pads of *NOD-SCID-IL2R $\gamma$ C<sup>-/-</sup>* mice (Jackson Laboratories) or were subcutaneously implanted in female HsdCpb:NMRI-*Foxn1<sup>tm</sup>* mice (Harlan Laboratories) at 6 weeks of age. For the PDX 127 model, animals were supplemented with 1  $\mu$ mol/L estradiol (Sigma) in the drinking water. After engraftment, tumor tissue was re-implanted into recipient mice, which were randomized when volumes reached 100–300 mm<sup>3</sup> to receive vehicle, veliparib or olaparib, dinaciclib, or the combination of PARP inhibitor and dinaciclib, with 5–10 mice/group. Animals were treated by oral gavage with veliparib (50 mg/kg twice daily) (Donawho et al., 2007), olaparib (50 mg/kg 6 days/week) (Juvekar et al., 2012), or with intraperitoneal dinaciclib (8 mg/kg 6 days/week for PDX 127 or 30 mg/kg twice weekly for PDXs 11-26 and 12-58) (Parry et al., 2010). Cisplatin was administered at 6 mg/kg (PDX 127) or 8 mg/kg (PDX 12-58) (Rotenberg et al., 2007). Caliper measurements were used to determine tumor volumes as length  $\times$  width<sup>2</sup>. Tumor volumes are plotted as mean  $\pm$  SEM.

### Immunofluorescence and Focal Microscopy

Primary antibodies recognizing BRCA1, RAD51, and  $\gamma$ -H2AX [pS139] were followed by secondary antibodies conjugated to fluorescein isothiocyanate (FITC) or Texas red (Jackson ImmunoResearch Laboratories). Confocal immunofluorescence images were acquired using Andor iQ software. For metaphase spreads, cells were exposed for 2 hr to Colcemid, harvested, and stained with Wright's stain. Fifty metaphase spreads were scored for aberrations, captured using CytoVision software (Applied Imaging).

### Histological and Immunohistochemical Staining

Formalin-fixed, paraffin-embedded sections of harvested xenografts were stained with H&E or antibodies against  $\gamma$ -H2AX [pS139] or RAD51. At least three xenografts, each with at least five 40 $\times$  fields, were manually scored or quantified by Aperio image analysis for each treatment. For toxicology assessments, mouse organs from vehicle- or combination-treated mice were harvested, formalin fixed, H&E stained, and evaluated histologically, as well as for  $\gamma$ -H2AX staining.

### Statistical Analysis

A p value <0.05 was considered statistically significant in two-tailed, unpaired Student's t tests.

### ACCESSION NUMBERS

The accession number for the gene expression analysis in vehicle- and dinaciclib-treated MDA-MB-231 cells is NCBI GEO: GSE88822.

### SUPPLEMENTAL INFORMATION

Supplemental Information includes Supplemental Experimental Procedures, seven figures, and one table and can be found with this article online at <http://dx.doi.org/10.1016/j.celrep.2016.10.077>.

### AUTHOR CONTRIBUTIONS

S.F.J., C.C., A.K.G., S.D., D.G.S., D.C., B.P., S.C., A.J.B., R.C., J.-B.L., B.K., H.S., C.U., L.A.M., K.A.S., S.J.R., V.S., and E.L. conducted the experiments.

R.C., M.S., D.J., J.B., A.L.R., J.B., V.S., and E.L. oversaw the procurement and establishment of PDX models, with overall coordination of in vivo experiments by E.L. S.F.J., A.D.D., J.B., N.J., M.G., V.S., E.L., and G.I.S. designed the experiments. S.F.J., M.G., and G.I.S. wrote the paper, which was reviewed and approved by all authors. G.I.S. supervised the entire project.

### ACKNOWLEDGMENTS

This work was supported by NIH grant R01 CA090687 (G.I.S.), an R01 CA090687 Research Supplement to Promote Diversity in Health-Related Research (S.F.J., G.I.S.), Dana-Farber Specialized Program of Research Excellence (SPORE) in Breast Cancer grant P50 CA168504 (G.I.S., A.D.D.), a P50 CA168504 SPORE Diversity Career Development Award (S.F.J. and G.I.S.), as well as Susan G. Komen Investigator Initiated Research grant IIR12223953 (G.I.S.). E.L. was supported by a Dana-Farber Claudia Adams Barr Award and a National Health and Medical Research Council of Australia Fellowship. Work at the Vall d'Hebron Institute of Oncology (VHIO) was supported by Instituto de Salud Carlos III grant PI12/02606 (J.B.) and the Asociación Española Contra el Cáncer (C.C.). M.G. is a member of the DFG excellence cluster ImmunoSensation and is supported by Deutsche Forschungsgemeinschaft grant GE 976/9-1. U2OS-pDR-GFP cells and Lenti-CRISPR/Cas9 constructs were provided by Maria Jasin and Jean Zhao, respectively. We thank Donna Skinner of the DF/HCC Research Pathology Core, Pilar Antón of VHIO, and Lan Hu of the DFCI Center for Cancer Computational Biology for technical assistance, as well as Bjoern Chapuy and Margaret Shipp for sharing preliminary data. S.J.R. has consulted for AstraZeneca. J.B. has received speaking bureau and travel fees from AstraZeneca and has served in an advisory role for Clovis Oncology. V.S. has a non-commercial research agreement with AstraZeneca. G.I.S. has received research funding from Merck & Co.

Received: February 8, 2016

Revised: September 8, 2016

Accepted: October 23, 2016

Published: November 22, 2016

### REFERENCES

- Alagpulinsa, D.A., Ayyadevara, S., Yaccoby, S., and Shmookler Reis, R.J. (2016). A cyclin-dependent kinase inhibitor, dinaciclib, impairs homologous recombination and sensitizes multiple myeloma cells to PARP inhibition. *Mol. Cancer Ther.* 15, 241–250.
- Bajrami, I., Frankum, J.R., Konde, A., Miller, R.E., Rehman, F.L., Brough, R., Campbell, J., Sims, D., Rafiq, R., Hooper, S., et al. (2014). Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity. *Cancer Res.* 74, 287–297.
- Balmaña, J., Tung, N.M., Isakoff, S.J., Graña, B., Ryan, P.D., Saura, C., Lowe, E.S., Frewer, P., Winer, E., Baselga, J., and Garber, J.E. (2014). Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors. *Ann. Oncol.* 25, 1656–1663.
- Bartkowiak, B., Liu, P., Phatnani, H.P., Fuda, N.J., Cooper, J.J., Price, D.H., Adelman, K., Lis, J.T., and Greenleaf, A.L. (2010). CDK12 is a transcription elongation-associated CTD kinase, the metazoan ortholog of yeast Ctk1. *Genes Dev.* 24, 2303–2316.
- Baumli, S., Lolli, G., Lowe, E.D., Troiani, S., Rusconi, L., Bullock, A.N., Debreczeni, J.E., Knapp, S., and Johnson, L.N. (2008). The structure of P-TEFb (CDK9/cyclin T1), its complex with flavopiridol and regulation by phosphorylation. *EMBO J.* 27, 1907–1918.
- Blazek, D., Kohoutek, J., Bartholomeeusen, K., Johansen, E., Hulinkova, P., Luo, Z., Cimerancic, P., Ule, J., and Peterlin, B.M. (2011). The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes. *Genes Dev.* 25, 2158–2172.
- Bösken, C.A., Farnung, L., Hintermair, C., Merzel Schachter, M., Vogel-Bachmayr, K., Blazek, D., Anand, K., Fisher, R.P., Eick, D., and Geyer, M. (2014). The structure and substrate specificity of human Cdk12/Cyclin K. *Nat. Commun.* 5, 3505.

- Bouwman, P., and Jonkers, J. (2014). Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors? *Clin. Cancer Res.* 20, 540–547.
- Bouwman, P., Aly, A., Escandell, J.M., Pieterse, M., Bartkova, J., van der Gulden, H., Hiddingh, S., Thanasoula, M., Kulkarni, A., Yang, Q., et al. (2010). 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. *Nat. Struct. Mol. Biol.* 17, 688–695.
- Bunting, S.F., Callén, E., Kozak, M.L., Kim, J.M., Wong, N., López-Contreras, A.J., Ludwig, T., Baer, R., Faryabi, R.B., Malhowski, A., et al. (2012). BRCA1 functions independently of homologous recombination in DNA interstrand crosslink repair. *Mol. Cell* 46, 125–135.
- Ceccaldi, R., O'Connor, K.W., Mouw, K.W., Li, A.Y., Matulonis, U.A., D'Andrea, A.D., and Konstantinopoulos, P.A. (2015). A unique subset of epithelial ovarian cancers with platinum sensitivity and PARP inhibitor resistance. *Cancer Res.* 75, 628–634.
- Donawho, C.K., Luo, Y., Luo, Y., Penning, T.D., Bauch, J.L., Bouska, J.J., Bontcheva-Diaz, V.D., Cox, B.F., DeWeese, T.L., Dillehay, L.E., et al. (2007). ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. *Clin. Cancer Res.* 13, 2728–2737.
- Eick, D., and Geyer, M. (2013). The RNA polymerase II carboxy-terminal domain (CTD) code. *Chem. Rev.* 113, 8456–8490.
- Garriga, J., and Graña, X. (2004). Cellular control of gene expression by T-type cyclin/CDK9 complexes. *Gene* 337, 15–23.
- Ghamari, A., van de Corput, M.P., Thongjuea, S., van Cappellen, W.A., van Ijcken, W., van Haren, J., Soler, E., Eick, D., Lenhard, B., and Grosveld, F.G. (2013). In vivo live imaging of RNA polymerase II transcription factories in primary cells. *Genes Dev.* 27, 767–777.
- Hill, S.J., Clark, A.P., Silver, D.P., and Livingston, D.M. (2014). BRCA1 pathway function in basal-like breast cancer cells. *Mol. Cell. Biol.* 34, 3828–3842.
- Johnson, N., Johnson, S.F., Yao, W., Li, Y.C., Choi, Y.E., Bernhardt, A.J., Wang, Y., Capelletti, M., Sarosiek, K.A., Moreau, L.A., et al. (2013). Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance. *Proc. Natl. Acad. Sci. USA* 110, 17041–17046.
- Joshi, P.M., Sutor, S.L., Huntoon, C.J., and Karnitz, L.M. (2014). Ovarian cancer-associated mutations disable catalytic activity of CDK12, a kinase that promotes homologous recombination repair and resistance to cisplatin and poly(ADP-ribose) polymerase inhibitors. *J. Biol. Chem.* 289, 9247–9253.
- Juvekar, A., Burga, L.N., Hu, H., Lunsford, E.P., Ibrahim, Y.H., Balmaña, J., Rajendran, A., Papa, A., Spencer, K., Lyssiotis, C.A., et al. (2012). Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. *Cancer Discov.* 2, 1048–1063.
- King, T.A., Li, W., Brogi, E., Yee, C.J., Gemignani, M.L., Olvera, N., Levine, D.A., Norton, L., Robson, M.E., Offit, K., et al. (2007). Heterogenic loss of the wild-type BRCA allele in human breast tumorigenesis. *Ann. Surg. Oncol.* 14, 2510–2518.
- Lam, L.T., Pickeral, O.K., Peng, A.C., Rosenwald, A., Hurt, E.M., Giltneane, J.M., Averett, L.M., Zhao, H., Davis, R.E., Sathyamoorthy, M., et al. (2001). Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol. *Genome Biol.* 2.
- Liang, K., Gao, X., Gilmore, J.M., Florens, L., Washburn, M.P., Smith, E., and Shilatifard, A. (2015). Characterization of human cyclin-dependent kinase 12 (CDK12) and CDK13 complexes in C-terminal domain phosphorylation, gene transcription, and RNA processing. *Mol. Cell. Biol.* 35, 928–938.
- Lok, B.H., Carley, A.C., Tchang, B., and Powell, S.N. (2013). RAD52 inactivation is synthetically lethal with deficiencies in BRCA1 and PALB2 in addition to BRCA2 through RAD51-mediated homologous recombination. *Oncogene* 32, 3552–3558.
- Mita, M.M., Joy, A.A., Mita, A., Sankhala, K., Jou, Y.M., Zhang, D., Statkevich, P., Zhu, Y., Yao, S.L., Small, K., et al. (2014). Randomized phase II trial of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus capecitabine in patients with advanced breast cancer. *Clin. Breast Cancer* 14, 169–176.
- Parry, D., Guzi, T., Shanahan, F., Davis, N., Prabhavalkar, D., Wiswell, D., Seghezzi, W., Paruch, K., Dwyer, M.P., Doll, R., et al. (2010). Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor. *Mol. Cancer Ther.* 9, 2344–2353.
- Rottenberg, S., Nygren, A.O., Pajic, M., van Leeuwen, F.W., van der Heijden, I., van de Wetering, K., Liu, X., de Visser, K.E., Gilhuijs, K.G., van Tellingen, O., et al. (2007). Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. *Proc. Natl. Acad. Sci. USA* 104, 12117–12122.
- Rottenberg, S., Jaspers, J.E., Kersbergen, A., van der Burg, E., Nygren, A.O., Zander, S.A., Derksen, P.W., de Bruin, M., Zevenhoven, J., Lau, A., et al. (2008). High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. *Proc. Natl. Acad. Sci. USA* 105, 17079–17084.
- Schlacher, K., Wu, H., and Jasin, M. (2012). A distinct replication fork protection pathway connects Fanconi anemia tumor suppressors to RAD51-BRCA1/2. *Cancer Cell* 22, 106–116.
- Scott, C.L., Swisher, E.M., and Kaufmann, S.H. (2015). Poly (ADP-ribose) polymerase inhibitors: recent advances and future development. *J. Clin. Oncol.* 33, 1397–1406.
- Tao, J.J., Castel, P., Radosevic-Robin, N., Elkabets, M., Auricchio, N., Aceto, N., Weitsman, G., Barber, P., Vojnovic, B., Ellis, H., et al. (2014). Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer. *Sci. Signal.* 7, ra29.
- Wang, Y., Zhang, T., Kwiatkowski, N., Abraham, B.J., Lee, T.I., Xie, S., Yuzugullu, H., Von, T., Li, H., Lin, Z., et al. (2015). CDK7-dependent transcriptional addiction in triple-negative breast cancer. *Cell* 163, 174–186.